CureVac's CVGBM Cancer Vaccine Induces Immune Responses In Phase 1 Study In Glioblastoma Presented At The ESMO 2024 Congress; Preliminary Immunogenicity Results Demonstrate Induction Of Cancer Antigen-Specific T-Cell Responses In 77% Of Evaluable Patients Following CVGBM Monotherapy
Portfolio Pulse from Benzinga Newsdesk
CureVac's CVGBM cancer vaccine shows promising results in a Phase 1 study for glioblastoma, with 77% of patients developing specific T-cell responses. The vaccine was well tolerated, and the recommended dose for further trials is 100 µg.
September 13, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CureVac's CVGBM cancer vaccine demonstrated promising Phase 1 results, inducing T-cell responses in 77% of patients with glioblastoma. The vaccine was well tolerated, with mild to moderate side effects, and 100 µg was selected for further trials.
The positive Phase 1 results for CureVac's CVGBM cancer vaccine, including a high rate of T-cell response and good tolerability, are likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100